Alexion's (AZN) ALXN1840 FoCus Phase III trial Met Primary Endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. HOOD
10. IBM

Go back to Alexion's (AZN) ALXN1840 FoCus Phase III trial Met Primary Endpoint

AstraZeneca's (AZN) Forxiga is Approved in Japan for Chronic Kidney Disease Treatment

August 26, 2021 5:37 AM EDT

AstraZeneca (NASDAQ: AZN) announces that Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in Japan for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D).

The approval by Japans Ministry of Health, Labour and Welfare (MHLW) is based on positive results from the DAPA-CKD Phase III trial.1 The decision follows the Priority Review designation granted by the MHLW... More

COVID vaccine protection wanes within six months - UK researchers

August 25, 2021 9:25 AM EDT

By William Schomberg and Ludwig Burger

LONDON (Reuters) -Protection against COVID-19 offered by two doses of the Pfizer/BioNTech and the Oxford/AstraZeneca vaccines begins to fade within six months, underscoring the need for booster shots, according to researchers in Britain.

After five to six months, the effectiveness of the Pfizer jab at preventing COVID-19 infection in the month after the second dose fell from 88% to 74%, an analysis of data collected in Britain's ZOE COVID study showed.

For the AstraZeneca vaccine, effectiveness fell from 77% to 67% after four to five months.

The study was... More